niacinamide has been researched along with Anoxemia in 58 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results of an analysis of the efficiency of using cytoflavin, a drug possessing cytoprotective and antihypoxemic properties, in a group of 215 patients with a diagnosis of acute carbon monoxide poisoning in 2004-2010 are compared to analogous data for 215 patients with same diagnosis treated in 1999-2004 without cytoflavin administration." | 9.15 | [Experience of cytoflavin administration for treating acute carbon monoxide poisoning]. ( Afanas'ev, VV; Petrova, AG; Provado, IP; Zobnin, IuV, 2011) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 7.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| "A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.79 | Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. ( Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M, 2013) |
| "Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation." | 7.79 | Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. ( Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T, 2013) |
| " Sorafenib has considerable anti-angiogenic effects that lead to tumor starvation and induce tumor hypoxia in the highly vascularized renal cell carcinoma (RCC) xenografts." | 7.78 | Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. ( Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y, 2012) |
| "Sorafenib was administered orally to mice bearing subcutaneous (SC, ectopic) or sub-renal capsule (SRC, orthotopic) tumors of murine (Renca) or human (786-O) RCC." | 5.34 | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. ( Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D, 2007) |
| "Results of an analysis of the efficiency of using cytoflavin, a drug possessing cytoprotective and antihypoxemic properties, in a group of 215 patients with a diagnosis of acute carbon monoxide poisoning in 2004-2010 are compared to analogous data for 215 patients with same diagnosis treated in 1999-2004 without cytoflavin administration." | 5.15 | [Experience of cytoflavin administration for treating acute carbon monoxide poisoning]. ( Afanas'ev, VV; Petrova, AG; Provado, IP; Zobnin, IuV, 2011) |
| ""ARCON" combines accelerated radiotherapy to counteract tumor repopulation with carbogen breathing and nicotinamide to reduce chronic and acute hypoxia." | 5.10 | ARCON: experience in 215 patients with advanced head-and-neck cancer. ( Bruaset, I; Kaanders, JH; Marres, HA; Merkx, MA; Pop, LA; van den Hoogen, FJ; van der Kogel, AJ, 2002) |
| " Sorafenib, the mainstay of treatment of HCC patients, however, leads to tumour hypoxia and thereby abrogates the efficacy of anti-PD-1 treatment." | 3.85 | CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. ( Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A, 2017) |
| "This study was aimed at determining the influence of cytoflavin on the morphological features of contractile cardiomyocytes in female rats after gestation and in newborn rats exposed to hemic hypoxia induced by sodium nitrite (NaNO(2))." | 3.83 | [MORPHOLOGICAL CHANGES IN RAT MYOCARDIUM EXPOSED TO HEMIC HYPOXIA AND TREATED WITH CYTOFLAVIN.] ( Sataeva, TP; Tret'yakova, OS; Zadnipryanyi, IV, 2016) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 3.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| "A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.79 | Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. ( Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M, 2013) |
| "Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation." | 3.79 | Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. ( Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T, 2013) |
| " Sorafenib has considerable anti-angiogenic effects that lead to tumor starvation and induce tumor hypoxia in the highly vascularized renal cell carcinoma (RCC) xenografts." | 3.78 | Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. ( Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y, 2012) |
| " Population spike amplitude (PSAP) and NADH were measured during hypoxic hypoxia (15 min) and recovery (45 min)." | 3.72 | Graded reoxygenation with chemical inhibition of oxidative phosphorylation improves posthypoxic recovery in murine hippocampal slices. ( Büchner, M; Huber, R; Riepe, MW; Spiegel, T, 2004) |
| " nicotinamide, isonicotinamide or nicotinic acid, as extra (axial) ligands, were tested in vivo on transplanted mice tumors, namely Lewis lung carcinoma (3LL), melanoma B16, and mammary adenocarcinoma Ca755." | 3.72 | Selectivity of effects of redox-active cobalt(III) complexes on tumor tissue. ( Bubnovskaya, L; Campanella, L; Ganusevich, I; Kovelskaya, A; Levitin, I; Osinsky, S; Sigan, A; Valkovskaya, N; Wardman, P, 2004) |
| "In both laryngeal squamous cell carcinoma xenograft tumour lines carbogen was very effective in reducing diffusion limited hypoxia." | 3.70 | Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. ( Bussink, J; Hodgkiss, RJ; Kaanders, JH; Marres, HA; Peters, JP; Rijken, PF; van der Kogel, AJ, 1999) |
| " The aims of this study were to compare in the rat isolated perfused lung preparation, the dilator actions of nicorandil, pinacidil and nitroglycerin on the hypoxic pulmonary pressure response with or without hypercapnic acidosis and to investigate the possible involvement of K channels and EDRF in these effects." | 3.69 | Comparison of the effects of nicorandil, pinacidil and nitroglycerin on hypoxic and hypercapnic pulmonary vasoconstriction in the isolated perfused lung of rat. ( Advenier, C; Dumas, JP; Dumas, M; Giudicelli, JF; Rochette, L, 1996) |
| "The myocardial protective effect of nicorandil, N-(2-hydroxyethyl) nicotinamide nitrate ester, against hypoxia was examined in comparison with that of nitroglycerin in 22 open chest dogs." | 3.67 | Examination of the direct effects of antianginal agents on the hypoxic canine myocardium. ( Hattori, S; Kojima, S; Miyamori, R; Miyazaki, T; Mori, H; Nagata, M; Nakamura, Y; Takahashi, M, 1987) |
| "Of 345 patients with cT2-4 laryngeal cancer, 174 were randomly assigned to accelerated radiotherapy and 171 to ARCON." | 2.79 | Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. ( Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Rademakers, SE; Span, PN; Takes, RP; Terhaard, CH; van den Ende, P, 2014) |
| "Strategies to correct hypoxemia have the potential to improve clinical outcomes in ARDS." | 1.48 | GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury. ( Bastarache, JA; Dufu, K; Hutchaleelaha, A; Lehrer-Graiwer, J; Li, CM; Majka, SM; Putz, ND; Shaver, CM; Ware, LB; Xu, Q, 2018) |
| " GBT1118 is a novel orally bioavailable small molecule that binds to hemoglobin and produces a concentration-dependent left shift of the oxygen-hemoglobin dissociation curve with subsequent increase in hemoglobin-oxygen affinity and arterial oxygen loading." | 1.43 | Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis. ( Dufu, K; Geng, X; Hutchaleelaha, A; Lehrer-Graiwer, J; Li, CM; Li, Z; Oksenberg, D; Patel, MP; Vlahakis, N; Xu, Q, 2016) |
| "Sorafenib was administered orally to mice bearing subcutaneous (SC, ectopic) or sub-renal capsule (SRC, orthotopic) tumors of murine (Renca) or human (786-O) RCC." | 1.34 | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. ( Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (18.97) | 18.7374 |
| 1990's | 9 (15.52) | 18.2507 |
| 2000's | 7 (12.07) | 29.6817 |
| 2010's | 28 (48.28) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Curran, CS | 1 |
| Dougherty, EJ | 1 |
| Cui, X | 1 |
| Li, Y | 1 |
| Jeakle, M | 1 |
| Gamble, T | 1 |
| Demirkale, CY | 1 |
| Torabi-Parizi, P | 1 |
| Liu, M | 1 |
| Zhou, P | 1 |
| Li, J | 1 |
| Jiang, Y | 1 |
| Dufu, K | 3 |
| Williams, AT | 1 |
| Muller, CR | 1 |
| Walser, CM | 1 |
| Lucas, A | 1 |
| Eaker, AM | 1 |
| Alt, C | 1 |
| Cathers, BE | 1 |
| Oksenberg, D | 2 |
| Cabrales, P | 1 |
| Yang, L | 1 |
| Taylor, J | 1 |
| Eustace, A | 1 |
| Irlam, JJ | 1 |
| Denley, H | 1 |
| Hoskin, PJ | 1 |
| Alsner, J | 1 |
| Buffa, FM | 1 |
| Harris, AL | 1 |
| Choudhury, A | 1 |
| West, CML | 1 |
| Putz, ND | 1 |
| Shaver, CM | 1 |
| Li, CM | 2 |
| Xu, Q | 2 |
| Hutchaleelaha, A | 2 |
| Lehrer-Graiwer, J | 2 |
| Majka, SM | 1 |
| Ware, LB | 1 |
| Bastarache, JA | 1 |
| Zabielska, MA | 1 |
| Adamus, J | 1 |
| Kowalski, R | 1 |
| Gebicki, J | 1 |
| Slominska, EM | 1 |
| Khalpey, Z | 1 |
| Smolenski, RT | 1 |
| Skrypko, V | 1 |
| Pasko, A | 1 |
| Churpiy, I | 1 |
| Kovalenko, A | 1 |
| Zaplutanov, V | 1 |
| Zadnipryanyi, IV | 1 |
| Tret'yakova, OS | 1 |
| Sataeva, TP | 1 |
| Iyer, P | 1 |
| Mayer, JL | 1 |
| Ewig, JM | 1 |
| Zhang, K | 1 |
| Waxman, DJ | 1 |
| Zinov'ev, EV | 1 |
| Nesterov, IuV | 1 |
| Lagvilava, TO | 1 |
| Janssens, GO | 1 |
| Rademakers, SE | 1 |
| Terhaard, CH | 1 |
| Doornaert, PA | 1 |
| Bijl, HP | 1 |
| van den Ende, P | 1 |
| Chin, A | 1 |
| Takes, RP | 1 |
| de Bree, R | 1 |
| Hoogsteen, IJ | 1 |
| Bussink, J | 2 |
| Span, PN | 1 |
| Kaanders, JH | 4 |
| Zhao, CX | 1 |
| Luo, CL | 1 |
| Wu, XH | 1 |
| Xu, H | 1 |
| Zhao, L | 1 |
| Fang, Q | 1 |
| Sun, J | 1 |
| Zhang, S | 1 |
| Zhan, C | 1 |
| Liu, S | 1 |
| Zhang, Y | 1 |
| Mouraret, N | 1 |
| Houssaïni, A | 1 |
| Abid, S | 1 |
| Quarck, R | 1 |
| Marcos, E | 1 |
| Parpaleix, A | 1 |
| Gary-Bobo, G | 1 |
| Dubois-Randé, JL | 1 |
| Derumeaux, G | 1 |
| Boczkowski, J | 1 |
| Delcroix, M | 1 |
| Blasco, MA | 1 |
| Lipskaia, L | 1 |
| Amsellem, V | 1 |
| Adnot, S | 1 |
| Jones, HD | 1 |
| Yoo, J | 1 |
| Crother, TR | 1 |
| Kyme, P | 1 |
| Ben-Shlomo, A | 1 |
| Khalafi, R | 1 |
| Tseng, CW | 1 |
| Parks, WC | 1 |
| Arditi, M | 1 |
| Liu, GY | 1 |
| Shimada, K | 1 |
| Wang, H | 1 |
| Liang, X | 1 |
| Luo, G | 1 |
| Ding, M | 1 |
| Liang, Q | 1 |
| Geng, X | 1 |
| Li, Z | 1 |
| Patel, MP | 1 |
| Vlahakis, N | 1 |
| Semaan, A | 1 |
| Dietrich, D | 1 |
| Bergheim, D | 1 |
| Dietrich, J | 1 |
| Kalff, JC | 1 |
| Branchi, V | 1 |
| Matthaei, H | 1 |
| Kristiansen, G | 1 |
| Fischer, HP | 1 |
| Goltz, D | 1 |
| Vasilyev, KY | 1 |
| Khazanov, VA | 1 |
| Fatullaeva, KF | 1 |
| Nurov, AU | 1 |
| Saltanov, AI | 1 |
| Livanov, GA | 1 |
| Amagyrov, VP | 1 |
| Batotsyrenov, BV | 3 |
| Lodiagin, AN | 1 |
| Batotsyrenova, KhV | 1 |
| Liu, J | 3 |
| Wu, JQ | 2 |
| Yang, JJ | 2 |
| Wei, JY | 2 |
| Gao, WN | 2 |
| Guo, CJ | 2 |
| Raskopf, E | 1 |
| Vogt, A | 1 |
| Decker, G | 1 |
| Hirt, S | 1 |
| Daskalow, K | 1 |
| Cramer, T | 1 |
| Standop, J | 1 |
| Gonzalez-Carmona, MA | 1 |
| Sauerbruch, T | 1 |
| Schmitz, V | 1 |
| Bi, J | 1 |
| Li, H | 1 |
| Ye, SQ | 1 |
| Ding, S | 1 |
| Zobnin, IuV | 1 |
| Petrova, AG | 1 |
| Provado, IP | 1 |
| Afanas'ev, VV | 1 |
| Murakami, M | 1 |
| Zhao, S | 1 |
| Zhao, Y | 1 |
| Chowdhury, NF | 1 |
| Yu, W | 1 |
| Nishijima, K | 1 |
| Takiguchi, M | 1 |
| Tamaki, N | 1 |
| Kuge, Y | 1 |
| Shilov, VV | 2 |
| Vasil'ev, SA | 1 |
| Kuznetsov, OA | 1 |
| Loladze, AT | 2 |
| Nojiri, K | 1 |
| Sugimoto, K | 1 |
| Shiraki, K | 1 |
| Tameda, M | 1 |
| Inagaki, Y | 1 |
| Ogura, S | 1 |
| Kasai, C | 1 |
| Kusagawa, S | 1 |
| Yoneda, M | 1 |
| Yamamoto, N | 1 |
| Takei, Y | 1 |
| Nobori, T | 1 |
| Ito, M | 1 |
| Andriaov, AY | 1 |
| Liang, Y | 1 |
| Zheng, T | 1 |
| Song, R | 1 |
| Wang, J | 1 |
| Yin, D | 1 |
| Wang, L | 1 |
| Liu, H | 1 |
| Tian, L | 1 |
| Fang, X | 1 |
| Meng, X | 1 |
| Jiang, H | 1 |
| Liu, L | 1 |
| INGALLS, TH | 1 |
| INGENITO, EF | 1 |
| CURLEY, FJ | 1 |
| Huber, R | 1 |
| Spiegel, T | 1 |
| Büchner, M | 1 |
| Riepe, MW | 1 |
| Osinsky, S | 1 |
| Levitin, I | 1 |
| Bubnovskaya, L | 1 |
| Sigan, A | 1 |
| Ganusevich, I | 1 |
| Kovelskaya, A | 1 |
| Valkovskaya, N | 1 |
| Campanella, L | 1 |
| Wardman, P | 1 |
| Jonathan, RA | 1 |
| Wijffels, KI | 1 |
| Peeters, W | 1 |
| de Wilde, PC | 1 |
| Marres, HA | 3 |
| Merkx, MA | 2 |
| Oosterwijk, E | 1 |
| van der Kogel, AJ | 3 |
| Chang, YS | 1 |
| Adnane, J | 1 |
| Trail, PA | 1 |
| Levy, J | 1 |
| Henderson, A | 1 |
| Xue, D | 1 |
| Bortolon, E | 1 |
| Ichetovkin, M | 1 |
| Chen, C | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Carter, CA | 1 |
| Taylor, IC | 1 |
| Lynch, M | 1 |
| Wilhelm, S | 1 |
| Akhundov, RA | 2 |
| Voronina, TA | 2 |
| Siess, M | 1 |
| Delabar, U | 1 |
| Seifart, HJ | 1 |
| Thomas, CD | 1 |
| Prade, M | 1 |
| Guichard, M | 1 |
| Dumas, M | 1 |
| Dumas, JP | 1 |
| Rochette, L | 1 |
| Advenier, C | 1 |
| Giudicelli, JF | 1 |
| Takizawa, T | 1 |
| Hara, Y | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Nakaya, H | 1 |
| Brown, JM | 1 |
| Wouters, BG | 1 |
| Hartmann, KA | 1 |
| Van der Kleij, AJ | 1 |
| Schneider, CJ | 1 |
| Sminia, P | 1 |
| Rijken, PF | 1 |
| Peters, JP | 1 |
| Hodgkiss, RJ | 1 |
| Vajragupta, O | 1 |
| Toasaksiri, S | 1 |
| Boonyarat, C | 1 |
| Wongkrajang, Y | 1 |
| Peungvicha, P | 1 |
| Watanabe, H | 1 |
| Boonchoong, P | 1 |
| Pop, LA | 1 |
| Bruaset, I | 1 |
| van den Hoogen, FJ | 1 |
| Horsman, MR | 3 |
| Chaplin, DJ | 2 |
| Trotter, MJ | 2 |
| Skov, KA | 1 |
| Zagorevskiĭ, VA | 1 |
| Overgaard, J | 1 |
| Christensen, KL | 1 |
| Leitold, M | 1 |
| Hader, S | 1 |
| Nakamura, Y | 1 |
| Kojima, S | 1 |
| Mori, H | 1 |
| Nagata, M | 1 |
| Miyazaki, T | 1 |
| Miyamori, R | 1 |
| Hattori, S | 1 |
| Takahashi, M | 1 |
| Nurmukhambetov, AN | 1 |
| Riabtseva, TA | 1 |
| Magour, S | 1 |
| Farah, A | 1 |
| Sroka, A | 1 |
| Severin, SE | 1 |
| Baran, LA | 1 |
| Surkov, GG | 1 |
| Berlet, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.[NCT00147732] | Phase 3 | 345 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Anoxemia
| Article | Year |
|---|---|
Nicotinamide and the hypoxia problem.
Topics: Humans; Hypoxia; Neoplasms; Niacinamide; Radiation Injuries; Radiation Tolerance | 1991 |
4 trials available for niacinamide and Anoxemia
| Article | Year |
|---|---|
Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Carbon Dioxide; Female; Hemoglobins; Humans; Hyp | 2014 |
[Experience of cytoflavin administration for treating acute carbon monoxide poisoning].
Topics: Adult; Carbon Monoxide; Carbon Monoxide Poisoning; Carboxyhemoglobin; Case-Control Studies; Drug Adm | 2011 |
[Pharmacologic correction of hypoxia in patients with acute cerebral failure due to acute poisoning with carbon monoxide and combustion products].
Topics: Acute Disease; Adult; Blood Gas Analysis; Carbon Monoxide Poisoning; Combined Modality Therapy; Crit | 2012 |
ARCON: experience in 215 patients with advanced head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Dose Fractionation, Radiation; Feasibility Studies; | 2002 |
53 other studies available for niacinamide and Anoxemia
| Article | Year |
|---|---|
Nicotinamide Antagonizes Lipopolysaccharide-Induced Hypoxic Cell Signals in Human Macrophages.
Topics: Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation; Lipopolysaccharides; Macro | 2023 |
Nicotinamide Inhibits Glycolysis of HL-60 Cells by Modulating Sirtuin 1 (SIRT1)/Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α)/Hypoxia-Inducible Factor-2α (HIF2α) Signaling Pathway.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Gene Expression Regulation; HL-60 Cells; Hu | 2020 |
Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.
Topics: Allosteric Regulation; Anemia, Sickle Cell; Animals; Benzaldehydes; Brain; Cerebral Cortex; Disease | 2021 |
A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
Topics: Aged; Carbon Dioxide; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Gene E | 2017 |
GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury.
Topics: Acute Lung Injury; Animals; Benzaldehydes; Disease Models, Animal; Drug Evaluation, Preclinical; Hyp | 2018 |
Cardioprotective effect of N-methylnicotinamide salt of pyruvate in experimental model of cardiac hypoxia.
Topics: Animals; Apolipoproteins E; Cardiotonic Agents; Creatine Kinase; Electrocardiography; Heart; Hypoxia | 2018 |
SURGICAL PREVENTION AND TREATMENT OF POSTOPERATIVE HYPOPARATHYROIDISM IN PATIENTS OPERATED ON THYROID GLAND.
Topics: Antioxidants; Drug Combinations; Flavin Mononucleotide; Humans; Hypoparathyroidism; Hypoxia; Inosine | 2018 |
[MORPHOLOGICAL CHANGES IN RAT MYOCARDIUM EXPOSED TO HEMIC HYPOXIA AND TREATED WITH CYTOFLAVIN.]
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Female; Flavin Mononucleotide; Hypoxia | 2016 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; | 2014 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Dise | 2013 |
[Experimental evaluation of reamberin and cytoflavin effects on the course and outcome of acute burn injury].
Topics: Acute Disease; Animals; Burns; Drug Combinations; Drug Evaluation, Preclinical; Female; Flavin Monon | 2013 |
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygen | 2015 |
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif | 2014 |
Role for telomerase in pulmonary hypertension.
Topics: Adult; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Female; Humans; Hyperte | 2015 |
Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.
Topics: Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage; CCAAT-Enhancer-Binding Proteins; Female; | 2015 |
Protection effect of nicotinamide on cardiomyoblast hypoxia/re-oxygenation injury: study of cellular mitochondrial metabolism.
Topics: Animals; Cell Line; Cell Survival; Cells, Cultured; Citric Acid Cycle; Dose-Response Relationship, D | 2016 |
Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.
Topics: Administration, Oral; Animals; Benzaldehydes; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen; Dys | 2016 |
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2017 |
Effect of cerebronorm on energy metabolism and lipid peroxidation in rat brain during hypoxia.
Topics: Animals; Brain; Energy Metabolism; Hypoxia; Inosine Diphosphate; Lipid Peroxidation; Male; Mitochond | 2007 |
[Correction of metabolic disturbances in cancer patients in the early postanesthesia period].
Topics: Adult; Aged; Anesthesia, General; Dose-Response Relationship, Drug; Drug Combinations; Female; Flavi | 2010 |
[Pharmacological correction of hypoxic and free-radical disorders in patients with acute myocardial infarction complicated by acute heart failure].
Topics: Acute Disease; Critical Care; Drug Combinations; Flavin Mononucleotide; Fluorocarbons; Free Radicals | 2010 |
Metabolomic study on vitamins B₁, B₂, and PP supplementation to improve serum metabolic profiles in mice under acute hypoxia based on ¹H NMR analysis.
Topics: Acute Disease; Animals; Dose-Response Relationship, Drug; Hypoxia; Lipid Metabolism; Magnetic Resona | 2010 |
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, | 2012 |
[Improvement effect of vitamins B1, B2 and PP supplementation on substance metabolism of mice exposed to acute hypoxia].
Topics: Animals; Carbohydrate Metabolism; Hypoxia; Lipid Metabolism; Male; Mice; Niacinamide; Proteins; Ribo | 2011 |
Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models.
Topics: Acrylamides; Animals; Brain; Cell Death; Cells, Cultured; DNA, Mitochondrial; Embryo, Mammalian; Fem | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; | 2012 |
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; | 2013 |
[Approaches to the improvement of treatment efficacy in patients with acute severe asaleptin intoxication complicated by acute respiratory insufficiency of mixed genesis].
Topics: Acute Disease; Adult; Antipsychotic Agents; Clozapine; Drug Combinations; Female; Flavin Mononucleot | 2012 |
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Li | 2013 |
ACQUIRED CHROMOSOMAL ANOMALIES INDUCED IN MICE BY KNOWN TERATOGEN.
Topics: Alloxan; Animals; Chromosome Aberrations; Cleft Palate; Embryo, Mammalian; Embryo, Nonmammalian; Fem | 1964 |
Graded reoxygenation with chemical inhibition of oxidative phosphorylation improves posthypoxic recovery in murine hippocampal slices.
Topics: Action Potentials; Amobarbital; Animals; Cyanides; Electron Transport Complex I; Electron Transport | 2004 |
Selectivity of effects of redox-active cobalt(III) complexes on tumor tissue.
Topics: Adenocarcinoma; Animals; Carcinoma, Lewis Lung; Cobalt; DNA Damage; Ethylenediamines; Female; Hypoxi | 2004 |
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbon Dioxide; Carbonic Anhy | 2006 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzene | 2007 |
[Nootropic and anxiolytic properties of endogenous ligands of benzodiazepine receptors and their structural analogs].
Topics: Amnesia; Amnesia, Retrograde; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Conflict, P | 1984 |
Cardiac synthesis and degradation of pyridine nucleotides and the level of energy-rich phosphates influenced by various precursors.
Topics: Adenine; Adenosine Triphosphate; Animals; Glycoside Hydrolases; Guinea Pigs; Hypoxia; Myocardial Con | 1983 |
Tumour oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and perflubron emulsion administration.
Topics: Animals; Carbon Dioxide; Cell Survival; Fluorocarbons; Humans; Hydrocarbons, Brominated; Hypoxia; Mi | 1995 |
Comparison of the effects of nicorandil, pinacidil and nitroglycerin on hypoxic and hypercapnic pulmonary vasoconstriction in the isolated perfused lung of rat.
Topics: Acidosis; Animals; Guanidines; Hypercapnia; Hypoxia; In Vitro Techniques; Lung; Male; Niacinamide; N | 1996 |
alpha 1-Adrenoceptor stimulation partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells: attenuation of the action potential shortening induced by hypoxia and K+ channel openers.
Topics: Action Potentials; Adrenergic alpha-Agonists; Animals; Benzopyrans; Cells, Cultured; Cromakalim; Fem | 1996 |
Comments on hyperbaric oxygen and carbogen/nicotinamide with fractionated radiation.
Topics: Carbon Dioxide; Humans; Hyperbaric Oxygenation; Hypoxia; Models, Biological; Neoplasms; Niacinamide; | 1997 |
Is hyperbaric oxygen more effective than carbogen/nicotinamide in tumor radiation response?
Topics: Animals; Carbon Dioxide; Hyperbaric Oxygenation; Hypoxia; Neoplasms, Experimental; Niacinamide; Oxyg | 1997 |
Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide.
Topics: Animals; Benzimidazoles; Blood Vessels; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Division; End | 1999 |
Chroman amide and nicotinyl amide derivatives: inhibition of lipid peroxidation and protection against head trauma.
Topics: Animals; Brain Injuries; Chromans; Craniocerebral Trauma; Disease Models, Animal; Dopamine; Electron | 2000 |
Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide.
Topics: Animals; Cell Survival; Cells, Cultured; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neopl | 1990 |
[Nootropic activity of nicotinamide and its structural analogs].
Topics: Amnesia; Animals; Hypoxia; Male; Meclofenoxate; Mice; Niacinamide; Piracetam; Psychotropic Drugs; Py | 1990 |
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy.
Topics: Animals; Benzimidazoles; Blood Pressure; Carcinoma, Squamous Cell; Cell Survival; Female; Fluorescen | 1989 |
[Influence of antianginal drugs on Lypressin induced T-wave enhancement in the electrocardiogram of the rat].
Topics: Administration, Oral; Angina Pectoris; Animals; Coronary Vasospasm; Electrocardiography; Hypoxia; Is | 1986 |
Examination of the direct effects of antianginal agents on the hypoxic canine myocardium.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiomyopathies; Coronary Circulation; Dogs | 1987 |
[Prevention of disorders of cardiac contractility with nicotinamide in adriblastin -related damage].
Topics: Animals; Cardiomyopathies; Doxorubicin; Heart Failure; Hypoxia; Myocardial Contraction; Niacinamide; | 1988 |
The partial purification of a carrier-like protein for organic bases from the kidney.
Topics: Aminohippuric Acids; Animals; Binding Sites; Carbon Isotopes; Centrifugation; Chromatography; Dibenz | 1969 |
[Basic directions in the study of the biochemistry of the myocardium].
Topics: Adaptation, Physiological; Animals; Camphor; Cardiac Glycosides; Cardiomegaly; Cardiovascular Diseas | 1967 |
[The effect of oxygen on the status of blood gases in oncological patients receiving radiation therapy].
Topics: Blood Gas Analysis; Carbon Dioxide; Humans; Hypoxia; Neoplasms; Niacinamide; Oxygen; Oxygen Consumpt | 1968 |
Effect of 6-amino-nicotinamide on the tolerance of mice to hypoxic hypoxia.
Topics: Amines; Animals; Blood Glucose; Body Temperature; Brain; Glucose; Hyperglycemia; Hypoxia; Male; Mice | 1974 |